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Abstract
Background: Neuroinflammation plays an important role in cerebral ischemia/reperfusion (I/R) injury. The P2X7
receptor (P2X7R) has been reported to be involved in the inflammatory response of many central nervous system
diseases. However, the role of P2X7Rs in transient global cerebral I/R injury remains unclear. The purpose of this study is
to determine the effects of inhibiting the P2X7R in a rat model of transient global cerebral I/R injury, and then to
explore the association between the P2X7R and neuroinflammation after transient global cerebral I/R injury.
Methods: Immediately after infusion with the P2X7R antagonists Brilliant blue G (BBG), adenosine
5′-triphosphate-2′,3′-dialdehyde (OxATP) or A-438079, 20 minutes of transient global cerebral I/R was induced using the
four-vessel occlusion (4-VO) method in rats. Survival rate was calculated, neuronal death in the hippocampal CA1
region was observed using H & E staining, and DNA cleavage was observed by deoxynucleotidyl transferase-mediated
UTP nick end labeling TUNEL). In addition, behavioral deficits were measured using the Morris water maze, and RT-PCR
and immunohistochemical staining were performed to measure the expression of IL-1β, TNF-α and IL-6, and to identify
activated microglia and astrocytes.
Results: The P2X7R antagonists protected against transient global cerebral I/R injury in a dosage-dependent manner. A
high dosage of BBG (10 μg) and A-0438079 (3 μg), and a low dosage of OxATP (1 μg) significantly increased survival
rates, reduced I/R-induced learning memory deficit, and reduced I/R-induced neuronal death, DNA cleavage, and glial
activation and inflammatory cytokine overexpression in the hippocampus.
Conclusions: Our study indicates that inhibiting P2X7Rs protects against transient global cerebral I/R injury by reducing
the I/R-induced inflammatory response, which suggests inhibition of P2X7Rs may be a promising therapeutic strategy
for clinical treatment of transient global cerebral I/R injury.
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Background
Transient global cerebral ischemia is one of the major
complications of clinical emergencies such as cardiac ar-
rest, drowning or severe systemic hypotension during a
surgical procedure. Currently, the most adequate treat-
ment for these patients is re-establishing perfusion of the
brain as soon as possible. However, reperfusion may
paradoxically exacerbate brain injury, which is called cere-
bral ischemia/reperfusion(I/R) injury [1]. Therefore, efforts
need be made that not only preserve cerebral blood flow,
but also prevent the actual mechanisms that trigger brain
damage after I/R injury [2].
Neuroinflammation, which is characterized by micro-
glial and astroglial activation, as well as the release of cyto-
toxic agents (cytokines, matrix metalloproteinases, nitric
oxide and reactive oxygen species) can be triggered by
cerebral I/R injury, which can contribute to blood–brain
barrier disruption and delayed neuronal death [3]. Subse-
quently, these damaged cells release more toxic mediators,
which in turn activate more immune cells. Thus, pro-
longed inflammation caused by this vicious circle exacer-
bates brain damage. Taken together, anti-inflammation
therapy may become a promising therapeutic strategy for
the treatment of cerebral I/R injury [3,4].
The P2X7 receptor(P2X7R), a purinergic receptor, was
first discovered in macrophages. In the central nervous
system (CNS), the P2X7R is predominantly expressed in
microglia which are the resident macrophages of the brain
[5]. The P2X7R can be activated by high concentrations of
ATP. Stimulating the P2X7R leads to microglial activation,
reactive oxygen species production and increased secre-
tion of pro-inflammatory cytokines such as IL-1ß, TNF-α
and IL-6 [6,7]. Recently, the P2X7R has been reported to
be involved in neuroinflammation in many CNS diseases
including Alzheimer’s disease (AD), epilepsy, spinal cord
injury and multiple sclerosis, and treatment with P2X7R
antagonists reduces experimentally induced neuroinflam-
mation in animal models of such diseases [6,8-12].
The P2X7R has also been reported to participate in
cerebral ischemic injury. In vitro and in vivo studies have
shown that inhibition of P2X7Rs reduced oxygen and
glucose deprivation-induced oligodendrocyte death [13] as
well as infarct volume after transient middle cerebral
artery occlusion(MCAO) injury [14,15]. However, ische-
mic injury exacerbation by P2X7R antagonists has also
been reported [16,17]. To date, the contribution of the
P2X7R to cerebral ischemic injury remains an issue, and
whether inhibition of P2X7R has beneficial or harmful
effects in global cerebral I/R injury has not been studied.
We, therefore, designed experiments using two widely
used P2X7R antagonists, Brilliant blue G (BBG) and
adenosine 5′-triphosphate-2′,3′-dialdehyde (OxATP) [6],
and the selective P2X7R antagonist A-438079 [18] to in-
vestigate the role of P2X7R in a rat model of transient
global cerebral I/R injury. We also explored the associ-
ation between the P2X7R and neuroinflammation after
transient global cerebral I/R injury.
Methods
Animals and surgical procedures
Male Sprague–Dawley rats weighing 260–320 g were pro-
vided by the Animal Center of Zhejiang University. All
procedures used in this study were carried out according
to the guidelines of the NIH Guide for the Care and Use
of Laboratory Animals and have been approved by the
Ethics Committee for the Use of Experimental Animals in
Zhejiang University.
Twenty minutes of global cerebral ischemia was induced
by the four-vessel occlusion (4-VO) method with slight
modification, as established by Pulsinelli [19], and rou-
tinely used in our laboratory [20,21]. Briefly, anesthesia
was induced with 4% (w/v) choral hydrate (400 mg/kg,
intraperitoneally (i.p.)), then the bilateral common carotid
arteries (CCAs) were freed and both vertebral arteries
were permanently electrocauterized. Rats were allowed to
recover for 24 hours after closing the surgical incisions.
On the following day (+0D), anesthesia was applied,
the surgical incision in the neck was opened and both
CCAs were occluded with aneurysm clips to induce
global cerebral ischemia. The clips were removed for
reperfusion. Rectal temperature was maintained at 36.5
to 37.5°C throughout the procedures. Cerebral blood
flow (CBF) before and after clamping the bilateral CCAs
was monitored using a laser Doppler blood flow monitor
(PeriFlux System5000, Perimed, Sweden), and rats with a
decrease in CBF of less than 80% were excluded [22].
Drug administration and experimental groups
To study the neuron survival rate in the hippocampal
CA1 region after transient global cerebral I/R injury, rats
were divided into eight groups: sham group (sham oper-
ated), saline group (I/R+ saline 2μL intracerebroventricu-
lar (i.c.v.), BBG (Sigma, St. Louis, MO) 1 μg, 5 μg, and
10 μg groups (I/R +BBG 1 μg/5 μg/10 μgi.c.v.), OxATP
(Sigma, St. Louis, MO) 1 μg, 5 μg, and10 μg groups (I/R +
OxATP 1 μg/5 μg/10 μgi.c.v.) and A-438079 (Tocris Bio-
science, Ellisville, MO) 0.03 μg, 0.3 μg, and 3 μg groups (I/
R +A-438079 0.03 μg/0.3 μg/3 μgi.c.v.). For the other
studies, rats were divided into five groups: sham group, sa-
line group, BBG 10 μg group(I/R+BBG 10 μg i.c.v.),
OxATP 1 μg group (I/R+OxATP 1 μg i.c.v.) and A-
438079 3 μg group (I/R+A-438079 3 μg i.c.v.).
Drug or saline was injected into the right cerebral
ventricle (AP −0.92 mm, ML 1.5, DV 3.5 mm) using a
microinjector. Drugs were administered into the lateral
cerebral ventricle 10 minutes prior to global cerebral
ischemia with a total volume of 2 μL at a speed of
0.5μL/minute.
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Sample preparation
After three (+3D) or seven days (+7D) of reperfusion,
rats were anesthetized and perfused intracardially with
saline, followed by 4%(w/v) paraformaldehyde in
0.1 mol/L PBS, pH= 7.4. Brains were removed and fixed
overnight in 4%(w/v) paraformaldehyde. Brains were em-
bedded in paraffin, and cut into 4 μm coronal sections
at the level of the bregma for H&E staining or
immunohistochemistry.
Morris water maze
At +8D, spatial learning and memory were tested using
the Morris water maze [23] which was a circular tank of
120 cm in diameter and 50 cm in height. The tank was
filled to a depth of 30 cm with water at 25± 1°C. The
water was made opaque by adding Chinese ink. The maze
was divided into four equal quadrants. The trials were per-
formed according to Vorhees’ method [24].
Spatial acquisition: All rats received a training trial con-
sisting of daily sessions of four consecutive trials for five
days. The hidden platform (diameter 10 cm, 1.5 cm below
the water surface) was positioned in the middle of the
southwest (SW) quadrant for all rats. The rats were
released into the tank facing the maze wall at north (N),
west (W), south (S), or east (E) quadrants in a predeter-
mined pseudorandom order. A trial was terminated as
soon as the rat found the platform; if the rat did not suc-
ceed within 120 seconds, it was guided onto the platform
with a stick. The rat was allowed to stay on the platform
for 20 seconds before being removed.
Probe trial: Immediately after the final training trial,
the platform was removed. Rats were released into the
pool at NE position and allowed to swim freely for 2
minutes. The time needed to find the platform (escape
latency) in the training trials and time spent in the SW
quadrant in the probe trial were recorded. The mean
value of four escape latencies in the daily four training
trials was taken as the escape latency for the rat. Values
from eight rats in the same group were averaged to gen-
erate a mean escape latency for that day. Brains of rats
in the behavioral study were removed after two weeks of
reperfusion and stained with H&E, and the surviving
neurons were counted.
Immunohistochemistry
Immunohistochemistry was performed according to the
protocol of Wang et al. [20]. Briefly, sections were pre-
pared at +3D using the same method mentioned in ‘sam-
ple preparation’. Sections were dewaxed with xylene and
dehydrated by ethanol at graded concentrations and
distilled water. Sections were then incubated for 10 min-
utes in 3%(v/v) hydrogen peroxide to block endogenous
peroxidase activity. High-temperature antigen retrieval
was performed in 0.01 M citrate buffer, pH 6.0, for 20
minutes. The brain sections were incubated overnight at
4°C with rabbit anti-Iba1 (ionized calcium-binding adaptor
molecule 1), immunoglobulin G(IgG) (diluted 1:500,
Wako, Osaka, Japan) or mouse anti-GFAP (glial fibrillary
acidic protein) IgG (diluted 1:50, Millipore, Bedford, MA,
USA) in PBS containing 0.3%(v/v) Triton X-100, followed
by incubation with EnVision (Zymed, San Francisco, CA,
USA) solution at 37°C for 30 minutes. Finally, sections
were incubated with peroxidase substrate diaminobenzi-
dine until a desired staining intensity developed, followed
by slight counterstaining with hematoxylin, dehydration,
and cover-slipping with permount. Between incubations,
the tissue was washed with PBS three times for 10 minutes
each.
In situ labeling of DNA fragmentation (terminal
deoxynucleotidyl transferase-mediated UTP nick end la-
beling (TUNEL)) was preformed with an in situ cell death
detection kit (Roche, Mannheim, Germany) according to
the manufacturer’s instructions.
RT-PCR
Hippocampi were rapidly isolated at +3D and total RNA
was extracted with TRIzol reagent(Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s protocol. RNA
(1 μg) was reverse transcribed using random primers
and M-MLV reverse transcriptase (Promega, Madison,
WI, USA) . The resulting cDNA amplification was per-
formed using the 7500 Fast Real-Time System (Applied
Biosystems, Foster City, CA, USA) in conjunction with
the SYBR Premix Ex TaqTM II kit (Takara, Japan). The
endogenous housekeeping gene, GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase), was used as a loading
control to normalize target gene expression. Each sam-
ple was analyzed in triplicate. Relative expression levels
of the target cDNAs were quantified by the 2-ΔΔCts
method. The target genes and the specific primers are
shown in Table 1.
Quantitative analysis
Neuronal damage and apoptosis were quantified by count-
ing the number of surviving neurons or immunopositive
neurons for TUNEL in the hippocampal CA1 layer.
Photomicrographs of the CA1 region were taken using a
Table 1 Details of primers (forward & reverse) for
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digital camera (Olympus DP20, Tokyo, Japan) connected
to an inverted microscope (Olympus BX51, Tokyo, Japan).
The numbers of surviving/TUNEL-positive neurons and
total neurons in the hippocampal CA1 layer per 1 mm
length were counted and analyzed by blinded investiga-
tors. The severity of neuronal damage/apoptosis was eval-
uated in the form of neuron survival rate/TUNEL-positive
neuron rate which was calculated by the number of sur-
viving or TUNEL-positive neurons/the number of total
neurons.
To quantify glial activation, we measured the value of
the integrated optical density (IOD) for Immunohisto-
chemistry images from the CA1 region stained with anti-
bodies against Iba-1 or GFAP using Image-Pro Plus 6.0
(Media Cybernetics, Bethesda, MD, USA). Pictures were
taken using the same method as mentioned above. Three
high power (400×) images were randomly selected for
each animal, and the mean IOD of these three fields was
considered as the IOD of the animal.
Statistical analysis
Values are expressed as the mean ± S.E.M. The Kaplan-
Meier method was used in the analysis for survival and
data were compared using the log-rank test (GraphPad
Prism 5). For analysis of escape latency in the behavioral
study two-way analysis of variance(ANOVA) was per-
formed. Other data were subjected to one-way ANOVA
and post-hoc comparisons were carried out using
Bonferroni’s test. Values of P< 0.05 were considered
significant.
Results
Inhibition of the P2X7R reduces I/R-induced neuron death
and neuronal DNA cleavage
To address the potential that inhibiting P2X7R prevents
transient global cerebral I/R injury, neuronal survival
was observed at +3D and +7D. Morphologically, most
neuronal death occurred within 72 hours (data not
shown). Only 10.8 ± 4.2% and 7.8 ± 3.3% of the
hippocampal CA1 neurons survived in the saline group
at +3D and +7D, respectively. All three P2X7R antago-
nists protected against transient global cerebral I/R in-
jury in a dose-dependent manner. BBG 5 μg and BBG
10 μg treatment significantly increased the neuron sur-
vival rate when compared to BBG 1 μg and saline; how-
ever, the BBG 10 μg was more effective (Figure 1A,B).
Rats receiving 1 μgOxATP had significantly more surviv-
ing hippocampal CA1 neurons than those receiving
other doses or saline (Figure 1A,C). Neuronal survival in
A-438079 treated animals was similar to survival rates in
those treated with BBG and A-438079 0.3 μg and A-
438079 3 μg treated animals, with significantly more sur-
viving hippocampal CA1 neurons when compared to the
A-438079 0.03 μg and saline groups (Figure 1A,D). Rats
from the A-438079 3 μg group had higher neuron sur-
vival rates than those from the OxATP 1 μg group
(87.8 ± 6.0% versus70.4 ± 8.6%). The neuron survival rate
in the BBG 10 μg and A-438079 3 μg group did not dif-
fer from each other at +7D.
Neuronal DNA cleavage induced by transient global
cerebral I/R injury was assessed by TUNEL at +3D. Most
of the morphologically damaged CA1 neurons were also
positive for TUNEL. The TUNEL-positive neuron rate
was 62± 10.1% in the saline group. The number of
TUNEL-positive CA1 neurons at +3D of reperfusion was
reduced almost completely in the BBG 10 μg (8± 2.8%),
OxATP 1 μg (11.3 ± 3.3%) and A-438079 3 μg (6.8± 2.4%)
groups. There was no significant difference among the
BBG 10 μg, OxATP 1 μg, A-438079 3 μg groups and the
sham group (Figure van A, E).
Inhibition of P2X7Rs increases survival rate
The survival rates of rats during the seven days after I/R in-
jury was significantly reduced in the BBG 10 μg (95.2%),
OxATP 1 μg(92.0%) and A-438079 3 μg (93.8%) treated
groups when compared to the saline group(72.4%). No sig-
nificant difference was observed among the BBG 10 μg,
OxATP 1 μg and A-438079 3 μg groups (Figure 2).
Inhibition of P2X7Rs improves I/R-induced behavioral
deficits
Spatial memory was evaluated using the Morris water
maze. During the five-day hidden platform trial, escape
latency of all the five groups decreased in a day-dependent
pattern. However, the sham group took significantly less
time to find the platform than the saline group on all five
days. In addition, the saline group required significantly
more time to find the platform than the BBG 10 μg and
A-438079 3 μg groups after the ninth day(+9D). The
OxATP 1 μg group took a significantly longer time to find
the platform than the A-438079 3 μg group after +9D and
a shorter time than the saline group after the eleventh day
(+11D). No significant differences existed among the
sham, BBG 10 μg and A-438079 3 μg groups (Figure 3A),
and no significant differences in swimming speed were
observed among the five groups (data not shown).
In the probe trial, the saline group spent significantly
less time than the other four groups in the SW quadrant.
There was no significant difference among the sham, BBG
10 μg group and OxATP 1 μg and A-438079 3 μg groups
(Figure 3B).
Inhibition of P2X7Rs reduces I/R-induced glial activation
To investigate the association between P2X7Rs and
ischemia-induced neuroinflammation, we evaluated
microglial and astroglial activation at +3D using an
immunohistochemistry method. Astrocytes were identi-
fied with an antibody against GFAP. In the sham group,
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only a few astrocytes with thin and long processes were
stained positive. However, a robust increase in GFAP
immunoreactivity and hypertrophic cellular morphology of
astrocytes was observed in the saline group. Treatment
with BBG 10 μg, OxATP 1 μg or A-438079 3 μg markedly
attenuated the increase in GFAP immunoreactivity com-
pared to the saline group (Figure 4A,B).
Iba-1 is a specific marker for microglia. Immunostaining
for Iba-1 revealed that in the sham group, only a few scat-
tered ramified microglia (resting microglia) were observed.
After three days of reperfusion, the number of microglia
was markedly increased in the hippocampal CA1 region,
the resting microglia turned into amoeboid-like cells with
plump cell bodies and short, thick processes which
reflected morphological features of activated microglia.
There was a significant decrease in microglial activa-
tion and infiltration in the BBG 10 μg, OxATP 1 μg
and A-438079 3 μg groups when compared to the sa-
line group (Figure 4A,C).
Inhibition of P2X7Rs attenuated I/R-induced cytokine
overexpression
To determine the effect of inhibiting P2X7Rs on
hippocampal inflammatory cytokine production, the ex-
pression levels of three cytokines, IL-1ß, TNF-α and IL-
Figure 1 Effect of BBG, OxATP and A-438079 on I/R-induced neuronal damage in the hippocampal CA1 region. (A) Representative H&E
staining of hippocampal CA1 neurons from the sham group, saline group, BBG 10 μg group, OxATP 1 μg and A-438079 3 μg groups at the
seventh day (+7D) (left) and representative TUNEL of hippocampal CA1 neurons from the sham group, saline group, BBG 10 μg group, OxATP
1 μg and A-438079 3 μggroups at the third day (+3D). (B) Neuron survival rate in the hippocampal CA1 region in BBG 1 μg, 5 μg and 10 μg
groups at +7D. (C) Neuronal survival rate in the hippocampal CA1 region in OxATP 1 μg, 5 μg and 10 μg groups at +7D. (D) Neuronal survival
rate in the hippocampal CA1 region in the A-438079 0.03 μg, 0.3 μg and 3 μg groups at +7D. (E) The percentage of TUNEL-positive neurons in
the hippocampal CA1 region in the sham, saline, BBG 10 μg, OxATP 1 μg and A-438079 3 μg groups at +3D. Values are expressed as the
mean± S.E.M. All photomicrographs are × 400. Scale bar: 10 μm. **P< 0.01 versus saline group; * P< 0.05 versus saline group; ##P< 0.01 versus
sham group; # P< 0.05 versus sham group. (n = 6 in all the groups). BBG, Brilliant blue G; I/R, ischemia/reperfusion; OxATP, adenosine 5′-
triphosphate-2′,3′-dialdehyde; S.E.M., standard error of the mean; TUNEL, deoxynucleotidyl transferase-mediated UTP nick end labeling.
Figure 2 Survival rate at seven days after transient global
cerebral I/R injury. Values are expressed as a percentage. * P< 0.05
versus saline group (n = 20, 28, 20, 22, 16 in sham, saline, BBG 10 μg,
OxATP 1 μg and A-438079 3 μg groups, respectively). BBG, Brilliant
blue G; I/R, ischemia/reperfusion; OxATP, adenosine 5′-triphosphate-
2′,3′-dialdehyde.
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6 were tested by RT-PCR at +3D. As expected, transient
global cerebral I/R significantly increased mRNA ex-
pression of IL-1ß, TNF-α and IL-6 in the hippocampus.
Administration of BBG 10 μg, OxATP 1 μg or A-438079
3 μg markedly attenuated the I/R-induced overexpres-
sion of IL-1ß, TNF-α and IL-6 (Figure 5).
Figure 3 Effect of BBG, OxATP and A-438079 on spatial learning and memory in the water maze. (A) Escape latency to find the platform
during the five days of thetraining trial from the eighth day (+8D) to the twelfth day (+12D) after reperfusion. (B) Time spent during the probe
trial in the quadrant where the platform had been located. Values are expressed as the mean± S.E.M. *P< 0.05 versus the corresponding value of
thesaline group on the same day; **P< 0.01 versus the corresponding value of the saline group on the same day; #P< 0.05 versus the
corresponding value of the sham group on the same day; ##P< 0.01 versus the corresponding value of the sham group on the same day; +
P< 0.05 versus the corresponding value of the OxATP 1 μg group on the same day; ++P< 0.01 versus the corresponding value of the OxATP
1 μg group on the same day (n = 15, 14, 13, 13, 10 in sham, saline, BBG 10 μg, OxATP 1 μg, A-438079 3 μg groups, respectively). BBG, Brilliant
blue G; OxATP, adenosine 5′-triphosphate-2′,3′-dialdehyde; S.E.M., standard error of the mean.
Figure 4 Effect of BBG, OxATP and A-438079 on I/R-induced astroglial and microglial activation. (A) Representative immunoreactivity for
GFAP (left) and Iba-1 (right) in the hippocampal CA1 region at the third day (+3D). (B) Quantitative analysis of IOD values of GFAP in the
hippocampal CA1 region at +3D. (C) Quantitative analysis of IOD values of Iba-1 in the hippocampal CA1 region at +3D. Values are expressed as
the mean± S.E.M. All photomicrographs are × 400. Scale bar: 10 μm. **P< 0.01 versus saline group; ##P< 0.01 versus sham group; #P< 0.05
versus sham group(n = 4 in all the groups). BBG, Brilliant blue G; GFAP, glial fibrillary acidic protein; IOD, integrated optical density; Iba1, ionized
calcium-binding adaptor molecule 1; I/R, ischemia/reperfusion; OxATP, adenosine 5′-triphosphate-2′,3′-dialdehyde; S.E.M., standard error of the
mean.
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Discussion
In this study, we demonstrated for the first time that inhi-
biting P2X7Rs protects against transient global cerebral I/
R injury via modulating inflammatory responses in the rat
hippocampus. When BBG and OxATP, two of the most
widely used P2X7R antagonists, and A-438079, a selective
P2X7R antagonist, were centrally administrated right be-
fore transient global cerebral I/R injury, they (1) reduced
mortality, neuronal cell death and behavioral deficits, and
(2) reduced the inflammatory responses as evidenced by a
reduction in microglial and astroglial activation, and
decreased inflammatory cytokine expression.
Cerebral ischemia rapidly increases inflammatory
responses in the rodent brain, which is characterized by
astroglial and microglial activation and inflammatory cyto-
kine release [2,25-27]. Transient global cerebral I/R leads
to selective tissue damage in the hippocampal CA1 region,
and neuronal death in the CA1 region after global cerebral
ischemia has occurred in a delayed manner [27,28]. In our
present study, apparent neuronal death was observed in
the hippocampal CA1 region in the saline group after
three to seven days of reperfusion, accompanied by
marked glial activation and cytokine overexpression (IL-
1ß, TNF-α and IL-6). Astroglial and microglial activation
in the hippocampus not only induces the production of
inflammatory cytokines but also reactive oxygen species,
chemokines, proteases, and vasoactive mediators many of
which are cytotoxic to neuronal cells [29]. Taken together,
our findings proved that neuroinflammation following
transient global cerebral I/R injury is an important con-
tributor to I/R-induced hippocampal CA1 neuron death.
The P2X7R is predominantly expressed by microglial
cells in the CNS. Numerous literature reports have shown
that P2X7R stimulation is related to microglial activation,
high doses of ATP that elicit microglia proliferation [30,31]
and morphological transformation [31], as well as super-
oxide production [32] and inflammatory cytokine secretion
[33,34] which could be inhibited by P2X7R antagonists.
Astrocytes normally express low levels of P2X7R [35-37].
However, the expression levels would be elevated in some
pathological conditions [38,39], thus the astroglial P2X7R
may be a direct target of ATP as an immunoregulator. Re-
cently, Jae et al. [9] reported that BBG reduced the activa-
tion of astrocytes and microglia as well as neuronal death
in the hippocampus of amyloid-ß1–42 (Aß1–42)-injected rats.
Pengetal. [8] also found that BBG treatment could attenuate
glial activation, tissue damage and behavioral deficits in a
rat spinal cord injury model. In agreement with these
studies, our data showed that BBG, OxATP and A-438079
reduced I/R-induced microglial and astroglial activation,
which was accompanied by reduced hippocampal CA1
neuron death, reduced apoptosis, and better spatial mem-
ory recovery(Figure 5), These results suggest that P2X7 re-
ceptor-mediated microglial and astroglial activation plays a
crucial role in neuronal damage in the hippocampal CA1
region following transient global cerebral I/R injury.
Reactive microglia and astrocytes can produce and re-
lease various inflammatory cytokines. Our results
showed that inhibition of P2X7Rs reduced the expres-
sion levels of IL-1ß, TNF-α and IL-6 after transient glo-
bal cerebral I/R injury. ATP is a potent inducer of IL-1ß
release as it activates the P2X7R-caspase 1 pathway [40].
The P2X7R also mediates TNF-α and IL-6 secretion
through diverse signal cascades [34,41]. In this study,
transient global cerebral I/R injury resulted in a substan-
tial increase in the expression levels of TNF-α, IL-1β,
and IL-6 in the rat hippocampus. We noted that in the
BBG 10 μg, OxATP 1 μg and A-438079 3 μg treated
groups, the levels of pro-inflammatory cytokines were
significantly suppressed, which suggests that inhibition
of the P2X7R effectively suppresses I/R-induced surges
in inflammatory cytokines in the hippocampus.
An increased number of P2X7R antagonists have been
identified and optimized by pharmaceutical companies and
academic groups. Among them, BBG and OxATP are the
most widely used in recent studies of P2X7Rs [6]. However,
both P2X7R antagonists suffer from relatively poor recep-
tor specificity. OxATP has strong antagonistic effects not
only on P2X7Rs, but also on other P2XRs [42,43], and even
P2YRs. BBG has nanomolar affinity on rat P2X7 receptors
and only micromolar affinity at some other P2XRs, and
used to be the most selective antagonist prior to applica-
tion of the selective P2X7R antagonist A-438079 in 2007
[43]. Our results show that all three P2X7R antagonists
can protect hippocampal CA1 neurons from global cere-
bral I/R injury. Rats receiving A-438079 3 μg had higher
neuron survival rates and better motor performance than
those receiving OxATP 1 μg. This may be due to the com-
plex mechanism of OxATP on other P2Rs, which has not
been well studied in cerebral ischemia.
Previous studies of Le Feuvreet al. [17] and Yanagi-
sawa et al. [16] failed to show any protective effect of
OxATP in MCAO models. OxATP is an irreversible an-
tagonist of P2X7Rs, which is widely used in studies of
P2X7Rs. OxATP in high concentrations have been
reported to be severely cytotoxic to cerebellar granule
neurons [6,44] and macrophages [6]. Although an
in vivo study [10] showed i.c.v. injection of high doses
(30 μg/day) of OxATP is safe for rats, the concentration
of the injected solution was relatively low (5 mM), and
the speed of injection was very slow (1.2 μg/hr). In the
study by Yanagisawaet al. [16], OxATP was injected (i.c.v)
at a concentration of 100 mM (totally 101 μg in 2 μL),
which is much higher than the OxATP concentration used
in our study (1 mM, totally 1 μg in 2μL). OxATP at high
doses and concentrations may be fatal to neuronal cells.
Le Feuvreet al. [17] used 3 mMOxATP (totally 3 μg in 2
μL) in a mouse MCAO model, and did not observe any
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Figure 5 Effect of BBG, OxATP and A-438079 on I/R -induced IL-1ß, TNF-α and IL-6 overexperession. Steady-state mRNA expression for IL-
1ß (A), TNF-α (B) and IL-6 (C) quantified by real-time RT-PCR. Expression is relative to GAPDH. Values are expressed as the mean± S.E.M. **P< 0.01
versus saline group; ##P< 0.01 versus sham group (n = 7 in all the groups). BBG, Brilliant blue G; GAPHD, glyceraldehyde-3-phosphate
dehydrogenase; IL-1ß, interleukin-1ß; IL-6, interleukin-6; I/R, ischemia/reperfusion; OxATP, adenosine 5′-triphosphate-2′,3′-dialdehyde; S.E.M.,
standard error of the mean; TNF-α, tumor necrosis factor α.
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protective effect of OxATP. Based on the report of Hibel-
let al. [45], apparent species differences exist in the kinetic
properties of P2X7R antagonists, thus the dosage used in
Le Feuvre’s study may not be optimal for mice. However,
further studies are needed to elucidate the pharmacokinet-
ics of different P2X7R antagonists in vivo.
Yanagisawa’s study [16] has shown that 2′, 3′-O-(4-
benzoyl-benzoyl)adenosine5′-triphosphate (BzATP), a
potent P2X7R agonist protected against MCAO injury
in rats. BzATP was widely used in studies of P2X7Rs, as
it exhibited at least 10- to 30-fold greater potency than
ATP [46]. However, BzATP was not a selective P2X7R
agonist; it could also bind to other P2X receptors, espe-
cially P2X1R, P2X2R and P2X3R, and has much more
potent effects on P2X1 and P2X3 receptors than
P2X7Rs [6,47]. Therefore, the mechanisms of BzATP-
induced neuroprotection in the rat brain may be far
more complicated than activation of P2X7Rs. Unfortu-
nately, to our knowledge, there are no available pharma-
cological ligands that can selectively activate the P2X7R
[47]. Further research should be aimed at developing
P2X7 agonists with greater pharmacologic specificity.
Conclusions
Overall, our study has shown that neuroinflammation
following transient global cerebral I/R injury is an im-
portant contributor to hippocampal CA1 neuron death,
and that inhibition of P2X7Rs protects against transient
global cerebral I/R injury by reducing I/R-induced in-
flammatory responses. These results indicate that block-
ing P2X7Rs may be a promising therapeutic strategy for
clinical treatment of transient global cerebral I/R injury.
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